

DAFTAR PUSTAKA

- Adhikari, N. K., Fowler, R. A., Bhagwanjee, S., Rubenfels, G. D., 2010, *Critical care and the global burden of critical illness in adults, The Lancet*, 376: 1339–1346.
- Angus, D. C., van der Poll, T., 2013, *Severe Sepsis and Septic Shock, NEJM*, 369(9): 840–851.
- Aslam, M., Tan, C. K., Prayitno, A., 2003, *Farmasi Klinis : Menuju Pengobatan Rasional & Penghargaan Pilihan Pasien*, 192, PT Elek Media Komputindo Gramedia, Jakarta
- Badan Pengawas Obat Dan Makanan Republik Indonesia (BPOM), 2014, *Informatorium Obat Nasional Indonesia*, Available at : <http://pionas.pom.go.id/ioni/bab-5-infeksi/51-antibakteri/512-sefalosporin-dan-antibiotik-beta-laktam-lainnya/5121> (Accessed: 10 Oktober 2018).
- Bari, S., Mahajan, B.M., Surana, S., 2008. *Resistance to antibiotic : A challenge in chemotherapy, IJPER*, 42(2); 3-11.
- Bearman, G. M., Wenzel, R. P., 2005, *Bacteremias: a leading cause of death, ARCH MED RES*, 36(6): 646–659.
- Berkowitz, D. M., Martin, G. S., 2007, *Sepsis and Sex Can We Look Beyond Our Hormones, Chest*, 132(6): 1725–1727.
- Berlanga, M., Viñas, M., 2000, *Salicylate induction of phenotypic resistance to quinolones in Serratia marcescens, JAC*, 46(2): 279–282.
- Bisht, R., Katiyar, A., Singh, R., Mittal, P., 2009, *Antibiotic resistance - A global issue of concern, AJPCR*, 2(2): 34–39.
- Biomérieux, 2016, *Blood Culture: a key investigation for diagnosis of bloodstream infection*, 36. Available at: http://www.biomerieux-usa.com/sites/subsidiary_us/files/blood_culture_booklet_-_prn_16_0097a_00_mk_approved13jul161.pdf (Accessed: 10 Oktober 2018).

- Budi, S., Ikawati, Z., Dwiprahasto, I., Nuryastuti, T., 2017, Evaluasi Drug Related Problems (DRPs) Antibiotik pada Pasien Sepsis di Rumah Sakit X Yogyakarta, *JIFL*, 15(1): 43-49.
- Chemsi, M., Hamid, H., Houari, S., Zerouali, K., Lehlimi, M., Ouhadous, M., *et al.*, 2016, *An Outbreak of Serratia marcescens on the Neonatal Unit: Description and Investigations J Infect Dis Ther*, 4: 306.
- Ciragil, P., Gul, M., Aral, M., Ekerbicer, H., 2006, *Evaluation of a new chromogenic medium for isolation and identification of common urinary tract pathogens, EJCMID*, 25(2): 108–111.
- Coulter S, Roberts JA, Hajkovicz K, H. K., 2017, *The use of bloodstream infection mortality to measure the impact of Antimicrobial Stewardship Interventions: Assessing the evidence, Inf Dis Rep*, 9(1): 6849.
- Dahesihdewi, A., Sugianli, A. K., Parwati, I., 2018, Data Surveilans Mikroba Dan Kepekaannya Terhadap Antibiotik Berdasarkan Tipe Rumah Sakit di Indonesia Tahun 2017, 18-31, Perhimpunan Dokter Spesialis Patologi Klinik dan Kedokteran Laboratorium Indonesia, Jakarta.
- Das, S, Sheorey, H. Taylor, H. R., Vajpayee, R. B., 2007, *Association between cultures of contact lens and corneal scraping in contact lens-related microbial keratitis, Arch Ophthalmol*, 125(9): 1182–1185.
- Dellinger, R. P., Lavy, M. M., Rhodes, A., Annane, D., Gertach, H., Opal, S. M., 2013, *Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock*, 2012, *ICM*, 39(2): 165–228.
- Dewi, R., 2011, Sepsis pada Anak: Pola Kuman dan Uji Kepekaan Sepsis in Children: Microbial Pattern and Susceptibility Test, *Maj Kedokt Indon*, 3: 101–106.
- Elahian, F., Moghimi, B., Dinmohammadi, F., Mahsa, G., Mehrdad, H., Seyed, A. M., 2013, *The Anticancer Agent Prodigiosin Is Not a Multidrug Resistance Protein Substrate, DCB*, 32(3): 90–97.
- Faidah, H., Ashgar, S. S., Barhameen, A., Alsaid, H. M., 2015, *Serratia marcescens as Opportunistic Pathogen and the Importance of Continuous Monitoring of Nosocomial Infection in Makah City, Saudi Arabia, OJMM*, 5: 107–112.

- Fitri, R., Ika, P., Djoko, W., 2016, Identifikasi Infeksi *Multidrug-Resistant Organisms* (MDRO) pada Pasien yang Dirawatdi Bangsal *Pediatric Intensive Care Unit* (PICU), *JMPF*, 6(1): 59-69.
- Friedman, N. D., Kotsanas, D., Brett, J., Billah, B., Korman, T. M., 2008, *Investigation of an outbreak of Serratia marcescens in a neonatal unit via a case-control study and molecular typing*, *Am. J. Infect. Control*, 36: 22–28.
- Galimand, M., Courvalin, P., Lambert, T., 2003, *Plasmid-Mediated High-Level Resistance to Aminoglycosides in Enterobacteriaceae Due to 16S rRNA Methylation These include : Plasmid-Mediated High-Level Resistance to Aminoglycosides in Enterobacteriaceae Due to 16S rRNA Methylation*, *AAC*, 47(8): 2565–2571.
- Herra, C. M., Knowles, S. J., Kaufmann, M. E., Mullvihi, E., McGrath, B., Keane, C. T., 1998, *An outbreak of an unusual strain of Serratia marcescens in two Dublin hospitals*, *J Hosp Infec*, 38: 5-141.
- Ibrahim, N. L., 2014, *A signaling pathway related to the activation of NF- κB*, *JPBS*, 2(3): 21–24.
- Jones, R. N., 2010, *Microbial Etiologies of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia*, *CID*, 51(9): 81–87.
- Kawecki, D., Kwiatkowski, A., Swaicka-Grzelak, A., Durluk, M., Paczek, L., Chmura, A., *et al.*, 2011, *Urinary Tract Infections in the Early Posttransplant Period After Kidney Transplantation: Etiologic Agents and Their Susceptibility*, *TTS*, 43(8): 2991–2993.
- Kementerian Kesehatan Republik Indonesia, 2015, *Penggunaan Antibiotik Bijak dan Rasional Kurangi Beban Penyakit Infeksi*. Available at: <http://www.depkes.go.id/article/view/15081100001/penggunaan-antibiotik-bijak-dan-rasional-kurangi-beban-penyakit-infeksi.html> (Accessed: 23 January 2018).
- Kementerian Kesehatan Republik Indonesia, 2012, *Indonesia Cinta Sehat*, Available at: www.promkes.depkes.go.id%5Cn36. (Accessed: 10 Oktober 2018).

- Khanna, A., Khanna, M., Aggarwal, A., 2013, *Serratia marcescens- a rare opportunistic nosocomial pathogen and measures to limit its spread in hospitalized patients*, *JCDR*, 7(2): 243–246.
- Klinger, G., Levy, I., Sirota, L., Boyko, V., Lerner-Geva, L., Reichman, B., 2010, *Outcome of early onset sepsis in national cohort of very low birth weight infant*, *AAP*, 125: 736-740.
- Kollef, M. H., Fraser, V. J., 2001, *Antibiotic resistance in the intensive care unit*, *ACP*, 134(4): 298–314.
- Laupland, K. B., 2013, *Incidence of bloodstream infection: a review of population-based studies*, *CMI*, 19(6): 492–500.
- Lidia, R. B., Gutierrez-Gonzalez, E., San Juan-Sanz, I., Fernandez-Jimenez, I., Ruiz-Carrascoso, G., Gallego-Lombardo, S., *et al.*, 2019, *Serratia marcescens outbreak in a neonatology unit of a Spanish tertiary hospital : Risk factors and control measures*, *AJIC*, 47(3): 271-279.
- Livermore, D. M., 1995, *beta-Lactamases in laboratory and clinical resistance*, *CMR*, 8(4): 557–84.
- Made Kardana, 2011, *Pola Kuman dan Sensitifitas Antibiotik di Ruang Perinatologi*, *Sari Pediatri*, 12(6): 381-385.
- Mahlen, S. D., 2011, *Serratia infections: From military experiments to current practice*, *CMR*, 24(4): 755–791.
- Maria, L. S., Marina, S., 2019, *Serratia marcescens Infections in Neonatal Intensive Care Units (NICUs)*, *IJERPH*, 16(4): 610.
- Martinez, R. M., Wolk, D. M., 2016, *Bloodstream Infections*, *ASMscience*, 4(1): 1–34.
- Menozzi, M. G., Eigner, U., Covan, S., Rossi, S., Somenzi, P., Dettori, G., *et al.*, 2006, *Two-center collaborative evaluation of performance of the BD phoenix automated microbiology system for identification and antimicrobial susceptibility testing of gram-negative bacteria*, *JCM*, 44(11): 4085–4094.

- Menteri Kesehatan Republik Indonesia, 2011, PERMENKES RI NO 2406/MENKES/PER/XII/2011 Tentang Pedoman Umum Penggunaan Antibiotik, 18-19.
- Merkier, A. K., Rodriguez, M. C., Togneri, A., Brengi, S., Osuna, C., Pichel, M., *et al.*, 2013, *Outbreak of a cluster with epidemic behavior due to Serratia marcescens after colistin administration in a hospital setting*, *JCM*, 51(7): 2295–2302.
- Michigan State University, 2011, *Antimicrobial Resistance Learning Site (AMRLS), Pharmacology Module Online*. Available at: <https://amrls.umn.edu/antimicrobial-resistance-learning-site> (Accessed: 31 January 2018).
- Młynarczyk, A., Młynarczyk, G., Pupek, J., Bilewska, A., Kawecki, D., Luczak, M., *et al.*, 2007, *Serratia marcescens Isolated in 2005 From Clinical Specimens From Patients With Diminished Immunity*, *TTS*, 39(9): 2879–2882.
- Pradipta, Surya, I., 2009, Evaluasi penggunaan antibiotik pada pasien sepsis di bangsal rawat inap penyakit dalam RSUP DR. Sardjito Yogyakarta periode September-November 2008, Thesis, Yogyakarta, Fakultas Farmasi Universitas Gadjah Mada Yogyakarta.
- Pratiwi S.T., 2008, Mikrobiologi Farmasi, 125-128, Erlangga, Jakarta.
- Koneman, E., Procop, G. W., Allen, S., Woods, G., Jenda, W., Washington Winn, J. R., 2016, *Koneman's Color Atlas and Textbook of Diagnostic Microbiology*, 450-455, Wolters Kluwer, China.
- Rahayu, E. U., 2011, Antibiotika, resistensi, dan rasionalitas terapi, *Saintis*, 1(4): 191–198.
- Rangel-Frausto, M. S., Pittet, D., Costigan, M., Hwang, T., Davis, C. S., 1995, *The natural history of the systemic inflammatory response syndrome (SIRS)*, *Jama*, 273(2): 117–23.

- Sader, H. S., Farrel, D. J., Flamm, R. K., Jones, R. N., 2014, *Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011)*, *DMID*, 78(4): 443–448. d
- Saravolatz L. D., Stein, G. E., Johnson, L. B., 2011, *Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus*, *CID*. 52(9): 1156–1163.
- Sari, D. P. P., 2016, *Kajian Penggunaan Antibiotik pada Terapi Empiris dengan Hasil Terapi Di Ruang Icu RSUD Dr. Moewardi Periode 2015*, Skripsi, Surakarta, Fakultas Farmasi Universitas Muhammadiyah Surakarta.
- Schwalbe, R., Steele-Moore, L., Goodwin, A. C., 2007, *Antimicrobial Susceptibility Testing Protocols*, CRC Press, United States, 200-210.
- Seliem, W. A. and Sultan, A. M., 2018, *Etiology of early onset neonatal sepsis in neonatal intensive care unit - Mansoura*, *JNPM*, 11(3): 323-330.
- Shah, G. S., 2006, *Risk factors in early neonatal sepsis*, *KUMJ*, 4: 87-91.
- Start B. L., 1998, *The Challenge of Antibiotic Resistance*, *Scientific American*, 46–53. Available at: http://eebweb.arizona.edu/Courses/Ecol409_509/levy.pdf. (Accessed: 10 Oktober 2018).
- Sun Bean, K., Jeon, Y. D., Kim, J. H., Ann, H. W., Choi, H., Kim, M. H., *et al.*, 2014, *Risk Factors for Mortality in Patients with Serratia marcescens Bacteremia*, *YMJ*, 56(2): 348-354.
- Tripathi, K. D., 2003, *Essential of medical pharmacology ed.5th*, 532-535, Jaypee brothers medical publishers, New Delhi.
- van der Vorm, E. R., Woldring-Zwaan, C., 2002, *Source, carriers, and management of a Serratia marcescens outbreak on a pulmonary unit*, *JHI*, 52(4): 63–267. d
- Veri, I., 2006, *Faktor Risiko Bakteremia Pada Pasien Bangsal Infeksi Penyakit Dalam Disertai Pola Kuman dan Pola Kepekaan* Skripsi, Semarang, Fakultas Kedokteran Universitas Diponegoro Semarang.
- Viscoli, C., 2016, *Bloodstream Infections: The peak of the iceberg*, *Virulence*, 7(3): 248–251.

- Viswanathan, R., Singh, A. K., Ghosh, C., Dasgupta, S., Mukherjee, S., Sulagna, B., 2012, *Profile of neonatal septicemia at a district level sick newborn care unit, JHPN*, 30(1): 41-48.
- Voelz, A., Muller, A., Gillen, J., Le, C., Dresbach, T., Engelhart, S., *et al.*, 2010, *Outbreaks of Serratia marcescens in neonatal and pediatric intensive care units: clinical aspects, risk factors and management, Int J Hyg Environ Health*, 213(2): 79-87.
- Wilar, R., Daud, D., Suryani, A., Febriani, D. B., Mina, 2016, *A comparison of neutrophil gelatinase-associated lipocalin and immature to total neutrophil ratio for diagnosing early-onset neonatal sepsis, Paediatrica Indonesiana*, 56(2): 107-10.
- World Health Organization, 2012, The evolving threat of antimicrobial resistance, Available at: <http://www.who.int/patientsafety/implementation/amr/publication/en/index.html>. (Accessed 1 April 2018).
- World Health Organization, 2001, WHO Global Strategy for Containment of Antimicrobial Strategy for Containment of Antimicrobial Resistance, 99. Available at: http://www.who.int/csr/resources/publications/drugresist/en/EGlobal_Strat.pdf (Accessed: 31 January 2018).
- Yoon, H. J., Choi, J. Y., Park, Y. S., Kim, C. O., Kim, J.M., *et al.*, 2005, Outbreaks of *Serratia marcescens* bacteriuria in a neurosurgical intensive care unit of a tertiary care teaching hospital: A clinical, epidemiologic, and laboratory perspective, *AJIC*, 33(10): 595–601.